Test your knowledge to see how well you remember our 2025 Resource Center

According to the Sequencing of Bispecific Antibodies and CAR T-Cell Therapies video, which characteristic is commonly used to identify a "functioning high-risk patient" who may warrant earlier consideration for CAR-T or bispecific therapy?

The patient has high disease burden requiring immediate admission for renal failure

The patient has a history of relapse within 1-2 years following an autologous stem cell transplant

The patient lives far from the tertiary center, complicating long-term follow-up

The patient's disease exhibits a slow progression rate

According to the Sequencing of Bispecific Antibodies and CAR T-Cell Therapies video, current institutional recommendations for patients starting bispecific therapy mandate starting IVIG only if the patient’s IgG level is below 400 mg/dL.

True

False

According to the Treatment of Intermediate Risk Smoldering Myeloma case study, which specific criterion immediately placed the patient into the intermediate-risk category for smoldering multiple myeloma?

Presence of the t(4;14) FISH abnormality

Monoclonal paraprotein (M spike) of 1.6 g/dL

Bone marrow biopsy demonstrating clonal plasma cells greater than 20%

IgA kappa subtype

According to the Treatment of Intermediate Risk Smoldering Myeloma case study, the patient experienced mild grade 1 fatigue during the 24 cycles of iberdomide monotherapy that required dose reduction, which also prevented the subsequent worsening of her baseline grade 1 peripheral neuropathy.

True

False

According to the Bispecific T-Cell Engager Therapy Administration and Management video, when considering moving the step-up dosing of bispecifics to an all-outpatient setting for select patients, which factor is crucial for eligibility?

The patient must have a prior history of Grade 1 CRS only

The patient must have local social support and live within a close proximity (e.g., 30 minutes) to the cancer center or hospital, which must also have trained emergency staff

The patient must have demonstrated no need for antimicrobial prophylaxis during initial treatment

The patient must be able to administer the subsequent full doses themselves

According to the Bispecific T-Cell Engager Therapy Administration and Management video, delays or modifications to the bispecific step-up dosing schedule due to toxicities like CRS are generally believed to significantly impact the patient's long-term treatment outcomes.

True

False

According to the Bispecific T-Cell Engager Therapy Considerations and Collaboration video, for patients with multiple myeloma, bispecific antibody therapy is currently positioned as:

Frontline therapy for newly diagnosed patients

Early relapse therapy following initial induction

Later-line therapy following exhaustion of many options in the multiple-relapse setting

A primary alternative to autologous stem cell transplant

According to the Bispecific T-Cell Engager Therapy Considerations and Collaboration video, the decision to administer prophylactic tocilizumab as part of the pre-medication regimen is based on the provider's perception of the patient's individual risk for cytokine release syndrome (CRS), particularly considering factors such as neutropenia or active infection.

True

False

According to the Relapsed Multiple Myeloma Treated with Teclistamab case study, which of the following is a recommended key measure for mitigating potential toxicities related to novel agents like bispecific antibodies?

Routine use of tocilizumab prior to step-up doses to prevent cytokine release syndrome

Immediate discontinuation of therapy if the patient develops persistent grade 1 anemia

Monitoring immunoglobulin levels with administration of IgG replacement if levels fall below 400 mg/dL

Withholding growth factor support for grade 3 neutropenia unless the ANC falls below 500/μL

According to the Relapsed Multiple Myeloma Treated with Teclistamab case study, teclistamab is a BCMA x CD3 bispecific antibody approved for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

True

False

According to the Innovations in Multiple Myeloma Treatment video, when subcutaneous daratumumab is used as monotherapy for high-risk smoldering myeloma, what is considered the major class of adverse event observed?

Peripheral neuropathy

Cardiac toxicity

Gastrointestinal bleeding

Infection

According to the Innovations in Multiple Myeloma Treatment video, the typical dosing schedule for subcutaneous daratumumab monotherapy in the high-risk smoldering myeloma setting involves weekly administration for the first four cycles, followed by biweekly, and then transitioning to monthly administration starting at Cycle 9.

True

False

According to the Emerging and Re-emerging Therapeutic Strategies in Multiple Myeloma video, in the Phase 1 study of the tri-specific T-cell engager ISB 2001, which finding was highlighted as a favorable safety and tolerability outcome, particularly compared to other T-cell engaging therapies?

Overall response rate of 36%

Median prior line of therapy was only 2

A low incidence of Grade 3 cytokine release syndrome

No neurological toxicity or treatment discontinuations due to AEs

According to the Emerging and Re-emerging Therapeutic Strategies in Multiple Myeloma video, patients with pre-existing severe ocular conditions may be less suitable candidates for belantamab-containing regimens due to the known potential for ocular toxicity, requiring more careful consideration and close monitoring.

True

False

According to the Linvoseltamab in Relapsed/Refractory Multiple Myeloma case study, the patient received linvoseltamab and experienced which adverse event during the initial step-up dosing?

Grade 2 neutropenia

Grade 1 cytokine release syndrome

Grade 1 peripheral neuropathy in both feet

Stringent complete response

According to the Linvoseltamab in Relapsed/Refractory Multiple Myeloma case study, patients who achieve a very good partial remission or better after 36 weeks can have their dosing reduced to every six weeks according to the approved dosing schedule for linvoseltamab.

True

False

According to the Highlights from the 2025 International Myeloma Society Annual Meeting video, data presented on bridging therapy prior to CAR-T infusion demonstrated that patients who achieved a partial response or better had correlations with which set of outcomes?

Increased non-relapse mortality and increased cytokine release syndrome

Decreased non-relapse mortality and increased progression-free survival

Decreased non-relapse mortality and increased T-cell expansion toxicity

Increased progression-free survival and increased incidence of Parkinsonism

According to the Highlights from the 2025 International Myeloma Society Annual Meeting video, updates on the MajesTEC-5 trial show that the combination of teclistamab, daratumumab, and lenalidomide, plus or minus bortezomib, resulted in low overall response rates, including 58% MRD-negativity, in the studied cohort.

True

False

According to the Outpatient Protocols and Patient Management of Bispecific Antibodies video, which medications do patients receive at home (in addition to acetaminophen and diphenhydramine) for self-administration should they develop concerning symptoms during the step-up dosing period?

Prophylactic tocilizumab and lorazepam

Ondansetron

Pocket dexamethasone

Mandatory antibiotics

It’s suggested in the Outpatient Protocols and Patient Management of Bispecific Antibodies video that because cytokine release syndrome (CRS) associated with bispecific antibodies is generally much less severe compared to CRS following CAR-T cell administration, the outpatient model is appropriate and shares clinical parallels with the historical adoption of rituximab or the management of neutropenic fever.

True

False

According to the Functional High-Risk Multiple Myeloma (FHRMM) case study, the patient met the definition of FHRMM due to which of the following events?

Initial diagnosis with R-ISS III staging

Acquisition of del(17p) during induction therapy

Early relapse 11 months after autologous stem cell transplantation

Failure to achieve a complete response after Dara-VRd induction

According to the Functional High-Risk Multiple Myeloma case study, at the time of his initial diagnosis, the patient had high-risk cytogenetics, specifically del(17p), which immediately placed him into the R-ISS III classification.

True

False